Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017:2017:7150386.
doi: 10.1155/2017/7150386. Epub 2017 Jul 6.

Association between HLA-DQ Gene Polymorphisms and HBV-Related Hepatocellular Carcinoma

Jingzhu Lv  1 , Tao Xu  2   3   4 , Zhongqing Qian  5   6 , Hongtao Wang  5   6
Affiliations
Review

Association between HLA-DQ Gene Polymorphisms and HBV-Related Hepatocellular Carcinoma

Jingzhu Lv et al. Gastroenterol Res Pract. 2017.

Abstract

Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related mortality worldwide. Host gene variants may influence hepatitis B virus- (HBV-) related HCC. Human leukocyte antigens (HLA) play an important role in presenting virus antigens to immune cells that are responsible for the clearance of virus-infected cells and tumor cells. Previous studies have investigated the HLA-DQ (rs2856718 and rs9275572) polymorphisms that may be associated with the development of HBV-related HCC. However, the results are controversial or inconclusive. Hence, we conducted a meta-analysis to derive a more precise estimation of the associations. A total of 6 articles were used to evaluate the effect of the two polymorphisms on the risk of HBV-related HCC. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated. We found that rs2856718 and rs9275572 in HLA-DQ significantly decreased HBV-related HCC in total population, especially in Chinese, but not in Saudi Arabian. Further validation of our results in larger populations and different ethnicities are required.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The flow charts of literature search and study selection.
Figure 2
Figure 2
Forest plots for HLA-DQ rs2856718 polymorphism and the risk of HBV-related HCC. (a) Overall meta-analysis of the relationship between HLA-DQ rs2856718 polymorphism and HBV-related HCC (HCC versus control) risk in dominant model (AG + GG versus AA). (b) Overall meta-analysis of the relationship between HLA-DQ rs2856718 polymorphism and HBV-related HCC (HCC versus CHB) risk in heterozygous model (AG versus AA).
Figure 3
Figure 3
Forest plots for HLA-DQ rs9275572 polymorphism and the risk of HBV-related HCC. (a) Overall meta-analysis of the relationship between HLA-DQ rs9275572 polymorphism and HBV-related HCC (HCC versus control) risk in dominant model (AA + AG versus GG). (b) Overall meta-analysis of the relationship between HLA-DQ rs9275572 polymorphism and HBV-related HCC (HCC versus CHB) risk in dominant model (AA + AG versus GG).
Figure 4
Figure 4
Sensitivity analysis of the pooled ORs and 95% CIs for HLA-DQ rs2856718 polymorphism. (a) The sensitivity analysis results of rs2856718 with HBV-related HCC (HCC versus control) in dominant model (AG + GG versus AA). (b) The sensitivity analysis results of rs2856718 with HBV-related HCC (HCC versus CHB) in heterozygous model (AG versus AA).
Figure 5
Figure 5
Sensitivity analysis of the pooled ORs and 95% CIs for HLA-DQ rs9275572 polymorphism. (a) The sensitivity analysis results of rs9275572 with HBV-related HCC (HCC versus control) in dominant model (AA + AG versus GG). (b) The sensitivity analysis results of rs9275572 with HBV-related HCC (HCC versus CHB) in dominant model (AA + AG versus GG).
See this image and copyright information in PMC

References

    1. Siegel R. L., Miller K. D., Jemal A. Cancer statistics, 2015. CA: A Cancer Journal for Clinicians. 2015;65(1):5–29. doi: 10.3322/caac.21254. - DOI - PubMed
    1. Ferlay J., Parkin D. M., Curado M. P., et al. Cancer Incidence in five Continents, Volumes I to X: IARC CANCER Base No. 10. 2014. http://ci5.iarc.fr.
    1. McGlynn K. A., Petrick J. L., London W. T. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clinics in Liver Disease. 2015;19(2):223–238. doi: 10.1016/j.cld.2015.01.001. - DOI - PMC - PubMed
    1. McGlynn K. A., London W. T. The global epidemiology of hepatocellular carcinoma: present and future. Clinics in Liver Disease. 2011;15(2):223–243. doi: 10.1016/j.cld.2011.03.006. - DOI - PMC - PubMed
    1. Parkin D. M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA: A Cancer Journal for Clinicians. 2005;55:74–108. doi: 10.3322/canjclin.55.2.74. - DOI - PubMed

LinkOut - more resources